Pharmacotherapies for cannabis use disorders: Clinical challenges and promising therapeutic agents
Date
2020
Authors
Nielsen, S.
Sabioni, P.
Gowing, L.
Le Foll, B.
Editors
Nadar, M.A.
Hurd, Y.L.
Hurd, Y.L.
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Book chapter
Citation
Substance Use Disorders: From Etiology to Treatment, 2020 / Nadar, M.A., Hurd, Y.L. (ed./s), vol.258, Ch.13, pp.355-372
Statement of Responsibility
Suzanne Nielsen, Pamela Sabioni, Linda Gowing, and Bernard Le Foll
Conference Name
Abstract
This chapter reviews pharmacotherapies that have been trialled for cannabis dependence, identifying those that warrant further research and those of little or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agonists warrant further research. For the FAAH inhibitor PF-04457845, oxytocin, varenicline and gabapentin, although there is a signal to indicate further research is warranted, these medications do not yet have sufficient evidence to support clinical use, and larger, longer-term trials are needed in representative treatment-seeking populations. Special populations that warrant consideration are those with cannabis dependence and concurrent mental health conditions and those that develop dependence through therapeutic use.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© Springer Nature Switzerland AG 2019